Quantcast
Home > Quotes > ACRS

Aclaris Therapeutics, Inc. Common Stock (ACRS) Quote & Summary Data

ACRS 
$1.47
*  
0.10
6.37%
Get ACRS Alerts
*Delayed - data as of Jan. 27, 2020  -  Find a broker to begin trading ACRS now
Exchange:NASDAQ
Industry: Health Care
View:    ACRS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
5
Today's High / Low
$ 1.55 / $ 1.4305
Share Volume
329,608
50 Day Avg. Daily Volume
641,733
Previous Close
$ 1.57
52 Week High / Low
$ 7.69 / $ 0.74
Market Cap
60,840,995
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.45
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
329,608
50 Day Avg. Daily Volume:
641,733

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.45

Trading Range

The current last sale of $1.47 is 98.65% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.55 $ 7.69
 Low: $ 1.4305 $ 0.74

Company Description (as filed with the SEC)

We are a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases. We have two commercial products and a diverse pipeline of drug candidates. Our first commercial product, ESKATA (hydrogen peroxide) topical solution, 40% (w/w), or ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution which was approved by the U.S. Food and Drug Administration, or FDA, in December 2017 as an office-based prescription treatment for raised seborrheic keratosis, or SK, a common non-malignant skin tumor. We launched ESKATA in the United States in May 2018. We also submitted a Marketing Authorization Application, or MAA, for ESKATA in select countries in the European Union, Norway and Iceland in July 2017 using a decentralized procedure.  ... More ...  



Risk Grade

Where does ACRS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.52
Open Date:
Jan. 27, 2020
Close Price:
$ 1.47
Close Date:
Jan. 27, 2020


Consensus Recommendation

Analyst Info